It will likely be years before these countermeasures are available, and it’s even more uncertain whether those who refuse vaccines would accept such treatments.

arstechnica.comAs US measles cases rise, biotech firms start developing new treatmentsThe US is making measles great again, so treatment options are needed for the most vulnerable.